Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 06, 2025 06:30 ET | Source: Rectify Pharmaceuticals, Inc.

Rectify Pharma Presents Translational Data Demonstrating Improvements in Kidney Function and Reductions in Vascular Calcification at ERA 2025

Potent, selective ABCC6-targeting positive functional modulator (PFM) improved multiple markers of renal function in animal models of chronic kidney disease (CKD) PFM improved inorganic pyrophosphate...
May 21, 2025 08:00 ET | Source: Rectify Pharmaceuticals, Inc.

Rectify Pharma to Present Translational Data on Novel Approach to Treat Chronic Kidney Disease and Vascular Calcification at ERA 2025

BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, Inc., (“Rectify”) a biotechnology company pioneering positive functional modulators (PFMs) that restore and enhance membrane protein...
May 09, 2025 06:00 ET | Source: Rectify Pharmaceuticals, Inc.

Rectify Pharma Presents Translational Data for Novel Positive Functional Modulator Demonstrating Improved Biliary and Liver Health at EASL 2025

Oral dual-targeted ABCB4/BSEP positive functional modulator (PFM) improved cholestatic and cholangitis markers in orthogonal models of hepatobiliary disease Data reinforce the potential of this...
April 23, 2025 08:00 ET | Source: Rectify Pharmaceuticals, Inc.

Rectify Pharma to Share Preclinical Data Highlighting Progress in Hepatobiliary Program at EASL 2025

BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, Inc., (“Rectify”) a biotechnology company pioneering positive functional modulators (PFMs) that restore and enhance membrane...
April 07, 2025 09:00 ET | Source: Rectify Pharmaceuticals, Inc.

Rectify Pharma Announces Publication of BSEP Transporter Biophysical Characterization in Communications Biology

Key structural and mechanistic insights into BSEP transporter mutations that lead to improper protein folding and function Findings have potentially broad-ranging clinical relevance for multiple...
November 18, 2024 08:00 ET | Source: Rectify Pharmaceuticals, Inc.

Rectify Pharma Presents Preclinical Data Supporting Development of Lead Candidate RTY-694 at The Liver Meeting® 2024

RTY-694 increased protein levels and function of ABCB4 and BSEP in primary hepatocytes, two transporters that play a key role in bile composition and bile flow Data demonstrate the potential of...
November 12, 2024 08:00 ET | Source: Rectify Pharmaceuticals, Inc.

Rectify Pharma to Host Virtual R&D Event on RTY-694 for Primary Sclerosing Cholangitis and Other Hepatobiliary Diseases on November 21, 2024

CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, Inc., (“Rectify”) a biotechnology company developing positive functional modulators (PFMs), small molecule therapeutics...
October 22, 2024 07:00 ET | Source: Rectify Pharmaceuticals, Inc.

Rectify Pharma Announces Positive Functional Modulator RTY-694 as Development Candidate for Primary Sclerosing Cholangitis

RTY-694 is a potent, orally active ABCB4/BSEP positive functional modulator (PFM) that improves bile composition and enhances bile flow The differentiated mechanism of a dual-targeted ABCB4/BSEP...
October 17, 2024 08:00 ET | Source: Rectify Pharmaceuticals, Inc.

Rectify Pharmaceuticals to Present New Preclinical Data at The American Association for the Study of Liver Diseases Annual Meeting

CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, Inc., (“Rectify”) a biotechnology company developing positive functional modulators (PFMs), small molecule therapeutics...
September 03, 2024 08:00 ET | Source: Rectify Pharmaceuticals, Inc.

Rectify Pharmaceuticals Appoints Pol Boudes as Chief Medical Officer

CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, Inc., (“Rectify”), a biotechnology company developing small molecule disease-modifying therapeutics that restore and...